Showing 5101-5110 of 5693 results for "".
- Not All With AMD May Need Continuing Treatmenthttps://modernod.com/news/not-all-with-amd-may-need-continuing-treatment/2477294/A small number of patients with neovascular age-related macular degeneration (AMD) continue to maintain good vision years after cessation of anti-VEGF therapy, according to an analysis of trial results, as reported by Reuters. Howe
- Kodiak Sciences Announces Additional Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-additional-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-diseases/2477282/Kodiak Sciences announced promising safety, efficacy, and durability data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular degener
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- ProQR Therapeutics Teams Up With Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People With Inherited Retinal Diseaseshttps://modernod.com/news/proqr-therapeutics-teams-up-with-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-tracker-program-for-people-with-inherited-retinal-diseases/2477280/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open-access program run by Blueprint Geneti
- FDA Approves CooperVision Biofinity Toric Multifocal Contact Lenseshttps://modernod.com/news/fda-approves-coopervision-biofinity-toric-multifocal-contact-lenses/2477277/The FDA has granted CooperVision approval for its new Biofinity toric multifocal contact lenses. The product combines the optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market1—and Biofinity multifocal to provide patients with astigmatism and pr
- Verana Health Acquires PYA Analytics; Announces $100 Million Financinghttps://modernod.com/news/verana-health-acquires-pya-analytics-announces-100-million-financing/2477275/Verana Health announced that it has acquired the assets of data science company PYA Analytics (PYAA). Based in Knoxville, Tennessee, PYAA specializes in large-scale data architecture solutions. Terms of the deal were not disclosed. PYAA was founded in 2013 by scientists and engineer
- Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases/2477274/AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore
- Nicox Receives Formulation Patent Extending NCX 470 US Patent Coverage to 2039https://modernod.com/news/nicox-receives-formulation-patent-extending-ncx-470-us-patent-coverage-to-2039/2477270/Nicox has received approval from the U.S. Patent and Trademark Office of a formulation patent for NCX 470, extending the U.S. patent coverage to 2039. NCX 470, a novel second gener
- Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Projecthttps://modernod.com/news/acucela-meets-with-nasa-and-trish-for-phase-1-update-for-ss-oct-project/2477272/Acucela announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health (TRISH)1 to present the status of its Swept Source-OCT (SS-OCT) device being developed for NASA’s Deep Space missions. The purpose of the meeting, which too
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis